Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Coronary Stents Market Size & Growth Forecast 2026–2035, By Segments (End Use, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11265| Published Date: Mar-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Coronary Stents Market size was more than USD 8.4 Billion in 2025 and is set to grow at a 2.6% CAGR between 2026 and 2035, exceeding USD 10.86 Billion by 2035. The industry revenue for 2026 is assessed at USD 8.59 billion.

Base Year Value (2025)
USD 8.4 Billion
CAGR (2026-2035)
2.6%
Forecast Year Value (2035)
USD 10.86 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Coronary Stents Market Intelligence Snapshot

Regional Market Dynamics

  • North America holds a 46.22% share, supported by advanced interventional cardiology infrastructure, widespread catheterization labs, and consistently high volumes of stent-based procedures across established healthcare systems.
  • Asia Pacific is expanding at a 2.96% CAGR, driven by rising access to minimally invasive cardiac care, expanding hospital capabilities, and increasing adoption of stent procedures in standard cardiovascular treatment pathways.

Segment Momentum

  • Drug Eluting Stents accounted for a 78.19% share in 2025, supported by broad clinical adoption, physician familiarity, and routine use within established coronary intervention protocols.
  • Outpatient Facilities are growing fastest because providers increasingly favor efficient treatment settings that support high patient throughput, shorter stays, and lower procedural resource requirements.

Market Expansion Drivers

  • Rising prevalence of coronary artery disease increasing demand for minimally invasive cardiac interventions.
  • Advancements in bioresorbable and drug-eluting stent technologies improving clinical adoption rates.
  • Expanding outpatient cardiac care infrastructure supporting broader stent-based treatment accessibility.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Key companies in the coronary stents market include Abbott Laboratories (USA), Medtronic plc (Ireland), Boston Scientific Corporation (USA), Terumo Corporation (Japan), BIOTRONIK SE & Co. KG (Germany), B. Braun SE (Germany), MicroPort Scientific Corporation (China), Cook Medical LLC (USA), SMT SA (Switzerland).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Rising prevalence of coronary artery disease increasing demand for minimally invasive cardiac interventions

As coronary artery disease becomes more common, patient volumes requiring revascularization continue to rise, pushing providers toward procedures that can restore blood flow quickly without the recovery burden of open-heart surgery. This dynamic is increasing demand for the coronary stents market because percutaneous coronary intervention fits the clinical and operational priorities of modern cardiac care: shorter hospital stays, faster treatment in acute cases, and the ability to manage a broader share of patients through catheter-based pathways. Hospitals and cardiology networks respond by expanding interventional capacity, standardizing stent use in treatment protocols, and increasing procurement of devices suited to different lesion types, all of which reinforces market demand.

Advancements in bioresorbable and drug-eluting stent technologies improving clinical adoption rates

Innovation in stent design is influencing market adoption by addressing the issues that most directly shape physician choice, particularly restenosis risk, long-term vessel healing, and procedural confidence in complex coronary cases. In the coronary stents market, newer drug-eluting platforms have strengthened clinician preference by improving deliverability and reducing repeat intervention concerns, while bioresorbable concepts continue to attract attention where long-term implant burden is a consideration. These technology gains affect purchasing decisions at the hospital level because interventional cardiologists tend to migrate toward devices that align with better patient management outcomes and support more consistent procedural performance.

Expanding outpatient cardiac care infrastructure supporting broader stent-based treatment accessibility

The spread of outpatient cardiac centers and ambulatory intervention capabilities is increasing market penetration by making stent-based treatment available beyond traditional tertiary hospital settings. For the coronary stents market, this changes how care is delivered in practice: stable patients can be diagnosed, treated, and discharged through more streamlined pathways, reducing capacity constraints and widening the addressable treatment base. As payers and providers place greater emphasis on procedural efficiency and site-of-care optimization, outpatient expansion supports higher procedure throughput and encourages investment in stent inventories tailored to routine coronary interventions.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising prevalence of coronary artery disease increasing demand for minimally invasive cardiac interventions 1.80% High North America, Asia Pacific High Near Term
Advancements in bioresorbable and drug-eluting stent technologies improving clinical adoption rates 1.60% High North America, Europe Medium Mid Term
Expanding outpatient cardiac care infrastructure supporting broader stent-based treatment accessibility 1.30% Moderate Asia Pacific, Latin America Emerging Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
46.22% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 46.22% share of the coronary stents market. This leadership is supported by the region’s established interventional cardiology infrastructure, broad availability of catheterization laboratories, and consistent use of stent-based procedures in the treatment of coronary artery disease. Market activity is further supported by routine diagnosis, strong procedural volumes, and the presence of major medical device manufacturers that enable steady product availability and clinician familiarity with advanced stent technologies.

Asia Pacific is projected to expand at a 2.96% CAGR over the forecast period in the coronary stents market, driven by rising adoption of minimally invasive cardiac procedures and expanding access to cardiovascular treatment across developing healthcare systems. Growth is being propelled by improving hospital capabilities, increasing patient access to interventional care, and a larger treated population as more healthcare providers incorporate stent procedures into standard cardiac management. These practical shifts in treatment delivery are accelerating regional demand as coronary interventions become more widely available across the care pathway.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Evidence-Based Cardiology Systems

Germany emphasizes coronary stents supported by strong clinical validation and structured cardiovascular treatment protocols. In Germany, hospitals prioritize long-term patient outcomes, device reliability, and integration with established interventional cardiology workflows across specialized cardiac centers.

France 🇫🇷

Structured Cardiac Treatment Pathways

France prioritizes coronary stents within standardized cardiovascular treatment pathways across public healthcare facilities. In France, clinical decisions focus on patient safety, regulatory compliance, and consistent use of well-established interventional cardiology devices.

Italy 🇮🇹

Interventional Cardiology Expansion

Italy continues to expand interventional cardiology capacity, supporting sustained use of coronary stents across regional hospital networks. In Italy, healthcare providers focus on balancing procedural accessibility with device reliability in routine and complex cardiac interventions.

Japan 🇯🇵

High-Risk Patient Management

Japan focuses on coronary stents used in managing complex cardiovascular cases and aging patient populations requiring precision intervention. In Japan, healthcare providers prioritize device flexibility, safety profiles, and compatibility with highly controlled clinical procedures.

South Korea 🇰🇷

Technology-Driven Cardiology Care

South Korea increasingly adopts advanced coronary stents within digitally enabled cardiac catheterization laboratories. In South Korea, hospitals emphasize procedural efficiency, device innovation, and integration with modern imaging and diagnostic support systems in cardiovascular care.

United States 🇺🇸

Advanced Cardiac Intervention

In the U.S., coronary stent usage is strongly tied to advanced interventional cardiology practices and rapid adoption of next-generation drug-eluting technologies. Cardiology centers prioritize devices that support complex lesion treatment, procedural safety, and reduced post-operative complications in high-volume cardiac care settings.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Coronary Stents Market Share (%), End Use, 2025

Outpatient Facilities
Inpatient Facilities

Go beyond the chart, access full insights & data tables

Request Free Sample Report
End Use Segment Analysis: Outpatient Facilities (Largest & Fastest-Growing Segment)

Outpatient Facilities held a 59.96% share of the coronary stents market in 2025, reflecting their established role in handling a high volume of routine coronary interventions with efficient patient throughput and controlled procedural costs. Their leadership is underpinned by the practical shift of suitable stent procedures toward less resource-intensive care settings, where standardized workflows, shorter stays, and expanding catheterization capabilities align well with payer and provider expectations. The same operating model is also sustaining growth momentum in the coronary stents market, as demand continues to favor treatment environments that can deliver timely intervention, procedural efficiency, and faster patient turnover without the infrastructure burden associated with more intensive inpatient settings.

Product Segment Analysis: Drug Eluting Stents (Largest Segment) vs Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents (Fastest-Growing Segment)

Drug Eluting Stents accounted for a 78.19% share of the coronary stents market in 2025, making them the clear leading product segment. Their continued dominance is rooted in broad clinical adoption, established physician familiarity, and routine integration into coronary intervention pathways, which together support consistent use across a wide base of procedures. In practical terms, the coronary stents market continues to favor Drug Eluting Stents because providers typically rely on product categories with well-established treatment protocols and dependable availability in everyday interventional settings.

Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents are the fastest-growing segment in the coronary stents market as treatment preferences increasingly pay attention to device approaches that align with longer-term vessel restoration goals. Their momentum relative to conventional alternatives comes from growing interest in solutions that provide temporary scaffolding rather than leaving a permanent implant in place, which is shaping adoption in settings where evolving interventional priorities support next-generation device uptake. As clinical decision-making gradually expands beyond immediate procedural outcomes alone, this positioning is helping Bioresorbable Vascular Scaffolds gain traction within the coronary stents market.

Segment Sub-Segment Largest Segment Fastest Growing
End Use Inpatient Facilities, Outpatient Facilities Outpatient Facilities Outpatient Facilities
Product Bare Metal Stents, Drug Eluting Stents, Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents Drug Eluting Stents Bioresorbable Vascular Scaffolds (BVS)/Bioresorbable Coronary Stents
Competitive Landscape

Competitive Landscape and Market Positioning

Key companies in the coronary stents market:

1. Abbott Laboratories (USA)

2. Medtronic plc (Ireland)

3. Boston Scientific Corporation (USA)

4. Terumo Corporation (Japan)

5. BIOTRONIK SE & Co. KG (Germany)

6. B. Braun SE (Germany)

7. MicroPort Scientific Corporation (China)

8. Cook Medical LLC (USA)

9. SMT SA (Switzerland)

The coronary stents market remains highly innovation-driven, supported by increasing focus on advanced cardiovascular treatment solutions. Industry participants are developing next-generation stents with improved drug-eluting capabilities, enhanced flexibility, and better long-term patient outcomes. Expanding clinical research efforts and advancements in minimally invasive cardiac procedures are also strengthening competition and accelerating technological progress in the market.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Nissha Jun-26 Nissha acquired a 60% stake in USM Healthcare Medical Devices Factory JSC in Vietnam, marking a strategic expansion into Southeast Asian cardiovascular stent manufacturing. This move enhances the company's regional production and distribution footprint, positioning it to better serve the growing interventional cardiology market in Asia through increased operational capacity and local manufacturing integration.
Artivion Apr-26 Artivion secured FDA pre-market approval for its aortic stent graft system, enabling immediate commercialization of the technology. The approval also triggered a buyout option for Endospan, a move that reinforces Artivion’s competitive positioning in advanced vascular and cardiac intervention technologies while accelerating the integration of specialized stent graft solutions into its broader clinical portfolio.
National Pharmaceutical Pricing Authority Apr-26 India’s NPPA revised price caps for coronary stents, setting drug-eluting stents at ₹39,186 and bare-metal stents at ₹10,762. This regulatory intervention significantly alters the pricing landscape for manufacturers operating in the Indian market, impacting margins and necessitating strategic adjustments to distribution and commercial models to maintain access and compliance within this high-growth clinical segment.
Abbott Mar-26 Abbott launched its XIENCE Skypoint drug-eluting stent in India, expanding its portfolio of advanced coronary intervention technologies. This rollout supports the company’s objective to strengthen its global leadership in interventional cardiology by providing next-generation stent solutions to a high-growth market, directly addressing the demand for enhanced efficacy and procedural safety in complex coronary care.
Uppsala University Sep-24 Researchers at Uppsala University developed a flexible stent designed to reduce complications in coronary artery surgery. The device's efficacy was evaluated against the conventional Resolute Onyx stent in the 2,400-patient Infinity-Swedeheart study. This innovation represents a significant technological advancement with potential to improve patient outcomes and define new performance benchmarks for future stent design and clinical application.
Silk Road Medical Mar-24 Silk Road Medical launched the Tapered ENROUTE Transcarotid Stent System in the U.S. market. The introduction of these tapered configurations expands the company’s existing portfolio of carotid solutions, providing physicians with specialized tools tailored to diverse patient anatomies and strengthening the company's competitive position within the niche segment of transcarotid interventions.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Coronary Stents Market — Custom Segments

Segment Sub-Segment
No segment data available.

Coronary Stents Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the current size of the coronary stents market?

The market revenue for coronary stents is anticipated at USD 8.59 billion in 2026.

How much is the coronary stents industry expected to grow by 2035?

Coronary Stents Market size is projected to expand significantly moving from USD 8.4 billion in 2025 to USD 10.86 billion by 2035 with a CAGR of 2.6% during the 2026-2035 forecast period.

How is the growing prevalence of coronary artery disease influencing treatment adoption in the coronary stents market?

Rising coronary artery disease cases are increasing demand for minimally invasive revascularization, pushing hospitals toward stent-based interventions that enable faster recovery, shorter stays, and higher procedural throughput, reinforcing standardized use in interventional cardiology pathways.

How are advancements in stent technology and outpatient cardiac care models shaping market expansion?

Improvements in drug-eluting and bioresorbable stents are increasing physician confidence and procedural consistency, while expansion of outpatient cardiac centers broadens access to interventions, raising procedure volumes and supporting higher adoption of stent-based treatment pathways.

Why do Drug Eluting Stents dominate the coronary stents market?

Drug Eluting Stents accounted for a 78.19% share in 2025, supported by broad clinical adoption, physician familiarity, and routine use within established coronary intervention protocols.

Why are Outpatient Facilities the fastest-growing end-use segment in the coronary stents market?

Outpatient Facilities are growing fastest because providers increasingly favor efficient treatment settings that support high patient throughput, shorter stays, and lower procedural resource requirements.

Why does North America dominate the coronary stents market?

North America holds a 46.22% share, supported by advanced interventional cardiology infrastructure, widespread catheterization labs, and consistently high volumes of stent-based procedures across established healthcare systems.

What is driving Asia Pacific’s growth in the coronary stents market?

Asia Pacific is expanding at a 2.96% CAGR, driven by rising access to minimally invasive cardiac care, expanding hospital capabilities, and increasing adoption of stent procedures in standard cardiovascular treatment pathways.

Who are the leading players in the coronary stents landscape?

Key companies in the coronary stents market include Abbott Laboratories (USA), Medtronic plc (Ireland), Boston Scientific Corporation (USA), Terumo Corporation (Japan), BIOTRONIK SE & Co. KG (Germany), B. Braun SE (Germany), MicroPort Scientific Corporation (China), Cook Medical LLC (USA), SMT SA (Switzerland).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →